Clinical Trial Update: DLL3-Targeted PET/CT in Neuroendocrine Carcinoma [NA]

View source ↗

Summary

A DLL3-targeted PET/CT imaging trial for DLL3-expressing neuroendocrine tumors is currently recruiting at The First Affiliated Hospital of Xiamen University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: DLL3-expressing Tumors, PET / CT | NA | Status: RECRUITING